Frequently asked questions about IMCIVREE

Acquired HO is a condition that affects weight and hunger in people who are brain tumor survivors, had treatment for brain tumors, or experienced a traumatic brain injury. Acquired HO is caused by injury to the hypothalamus, a key control center for hunger and calorie use in the brain.

Acquired HO is a distinct and diagnosable medical condition. It’s important to know that changes in weight or hunger associated with acquired HO are the result of an injury to your hypothalamus and can be hard to control on your own.

Weight gain from acquired HO is directly linked to an injury to the hypothalamus that affects the brain’s ability to manage weight, hunger, and how calories are used. The hypothalamus sends and receives signals using different pathways in the brain. The MC4R pathway (or the melanocortin-4 receptor pathway) is a key pathway for signals about hunger, fullness, and calorie use. When this pathway is impaired, it can lead to weight gain and increased hunger.

IMCIVREE is designed to reestablish the function of the MC4R pathway so messages between the brain and the body are able to get through again. The brain can regulate fullness and calorie use, which supports weight loss and long-term weight management.

Each individual is different and results can vary from person to person. In the clinical trial, IMCIVREE delivered significant, rapid, and sustained weight loss and hunger reduction. Please visit here to see more about the IMCIVREE study results.

IMCIVREE should be injected once daily at the beginning of the day, and can be given at home with or without food.

IMCIVREE was studied and approved as a daily injection that targets MC4R pathway impairment. Staying on IMCIVREE is important to maintain long-term reductions in weight.

If a dose of IMCIVREE is missed, inject the next dose at the regularly scheduled time the next day. Do not take the missed dose of IMCIVREE.

Please note that each person is different and results can vary from one person to another. Please talk to your doctor about your own treatment expectations. In a Phase 3 clinical trial dedicated to obesity and hunger reduction in people with acquired HO, meaningful weight reduction as measured by BMI began within 4 weeks and continued over time.

We encourage you to reach out to your doctor for more information about nausea and vomiting. Individual responses may vary but in the clinical trials, nausea and vomiting were more frequently reported within the first month of treatment and then declined.

Patients with acquired HO may have related disorders such as central diabetes insipidus (also known as arginine vasopressin deficiency) or adrenal insufficiency. If you have diabetes insipidus or adrenal insufficiency, make sure to talk with your doctor.

Distraction can often help reduce fear when giving injections to children. Have your child try:

• Deep (tummy) breathing
• Reading or looking at a book
• Watching TV or a movie
• Squeezing a stuffed animal
• Listening to music
• Playing a video game

Developing a routine and doing it the same way every day can help build your confidence and reassure your child.

A Patient Education Manager (PEM)* can give you and your child personalized support to help you on your treatment journey with IMCIVREE. We invite you to contact Rhythm InTune at 1-855-206-0815 or patientsupport@rhythmtx.com.

Please reach out to your doctor if you have any questions about IMCIVREE. You can use our Doctor Discussion Guide to help you start the conversation. For information about Rhythm's patient support program, please contact Rhythm InTune at 1-855-206-0815 or patientsupport@rhythmtx.com.

Rhythm InTune is a support program that can provide resources, education, and information tailored to fit the unique needs of people living with acquired HO. We invite you to contact Rhythm InTune at 1-855-206-0815 or patientsupport@rhythmtx.com.